Critical appraisals and clinical takeaways that separate signal from noise.

OPTION Trial tenecteplase for non-LVO stroke (late window, CT perfusion selected)

The OPTION Trial: Late-Window TNK for Non-LVO Stroke

The OPTION trial evaluated IV tenecteplase (0.25 mg/kg) in CT perfusion–selected non-LVO ischemic stroke patients treated 4.5–24 hours after last-known-well. Tenecteplase improved excellent 90-day outcomes (mRS 0–1) but increased symptomatic ...

Neurology

Evidence-based • Practical • Trusted by millions of clinicians each year

Get new posts (free)

1 email per week. No spam.

Sponsored

Get new posts (free)

1 email per week. No spam.

Sponsored